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A novel phenotyping strategy in schizophrenia, targeting different neurocognitive domains, neurobehavioral features,
and selected personality traits, has allowed us to identify a homogeneous familial subtype of the disease, characterized
by pervasive neurocognitive deficit. Our genome scan data indicate that this subtype, which accounts for up to
50% of our sample, has a distinct genetic basis and explains linkage to chromosome 6p24 reported previously. If
representative of other populations, the ratio of schizophrenia subtypes observed in our families could have a
profound impact on sample heterogeneity and on the power of genetic studies to detect linkage and association.
Our proposed abbreviated battery of tests should facilitate phenotype characterization for future genetic analyses
and allow a focus on a crisply defined schizophrenia subtype, thus promoting a more informed search for suscep-
tibility genes.
The argument about whether schizophrenia (MIM
181500) is a single disease or a collection of pathoge-
netically distinct subtypes goes back to the inception of
the diagnostic concept at the turn of the 20th century.
E. Kraepelin (1909) viewed dementia praecox as a cog-
nitive disorder, sometimes accompanied by delusions,
hallucinations, and excitement, but essentially charac-
terized by “weakening of the mainsprings of volition,”
“lowered mental efficiency,” “unsteadiness of atten-
tion,” “inability to sift, arrange and correct ideas, and
to accomplish mental grouping of ideas” (pp. 7–74).
Coining the term “schizophrenia” to replace “dementia
praecox,” E. Bleuler (1920) emphasized that it “is not
a disease in the strict sense, but appears to be a group
of diseases…Therefore we should speak of schizophre-
nias in the plural” (p. 373).
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The inherent heterogeneity of the original concept has
been obfuscated in modern diagnostic classifications
(DSM-IV and ICD-10), which are designed to meet the
needs of patient management, not fundamental research;
which give primacy to subjective symptoms; and which
may not target phenotypes anchored in the biology of
the illness (Heinrichs 2004). Limited understanding of
phenotypic heterogeneity is a common challenge in ge-
netic studies of complex disorders and is a major con-
tributor to the slow progress of such studies. The search
for susceptibility genes in schizophrenia is particularly
aggravated by the dual predicament of likely etiologi-
cal diversity and a potentially fallible phenotype based
on the diagnostic classifications of psychopathological
phenomena.
In this study, we adopted, from the outset, the original
concept (Bleuler 1920) of schizophrenia as an amalgam
of several underlying, etiologically distinct disorders,
and we argue that objective measures of brain dysfunc-
tion are likely to facilitate their delineation. Recent evi-
dence has indicated that patients with schizophrenia ex-
hibit abnormalities in multiple cognitive domains that
predate the onset of the disorder (Kremen et al. 1998;
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Bilder et al. 2000), persist across changes in the clinical
state (Hoff et al. 1999), are not attributable to anti-
psychotic medications (Torrey 2002), occur in nonpsy-
chotic relatives (Sitskoorn et al. 2004), and are specific
to schizophrenia, as compared with other psychotic
disorders (Altshuler et al. 2004), which thus meets the
criteria for an endophenotype (Gottesman and Gould
2003). We reasoned that such abnormalities reflect pat-
terns of deficit across multiple cognitive functions and
domains; therefore, searching for distinct illness sub-
types on the basis of a single or a few such traits is
unlikely to produce coherent results, because of small
individual effect sizes and the extraordinary variability
that characterizes the cognitive performance of patients
with schizophrenia (Heinrichs 2004). We adopted a
novel phenotyping strategy, aiming to identify composite
profiles of cognitive performance. We employed a bat-
tery of tests (Hallmayer et al. 2003), targeting different
neurocognitive domains, neurobehavioral features, and
selected personality traits.
The study included a total of 531 Western Australian
subjects of European descent: 388 members of 112 fam-
ilies affected by schizophrenia and 143 population con-
trols. The families were ascertained through affected
probands by monitoring of consecutive admissions to a
psychiatric hospital. Probands and first-degree relatives
underwent a diagnostic assessment based on a structured
interview with the use of Schedules for Clinical Assess-
ment in Neuropsychiatry (SCAN), version 2.0 (Wing et
al. 1990), a review of case records, and a structured
developmental history obtained from a key family mem-
ber. Full pedigree descriptions and family histories were
collected using the National Institute for Mental Health
Family Interview for Genetic Studies. Research diag-
noses were established by consensus between two senior
clinicians (blinded to family relatedness), who reviewed
independently all diagnostic information, including the
videotape of the SCAN interview, and assigned ICD-10
and DSM-IV lifetime diagnoses. The 388 family mem-
bers (of whom 145 were parents and 131 were siblings
of probands) included 138 affected individuals with
schizophrenia or schizophrenia spectrum disorders (SZ/
SZS), which include schizoaffective disorder, schizotypal
personality disorder, and other nonaffective psychoses.
The 143 control subjects (73 females and 70 males),
recruited from a list of Red Cross blood donors or by
random sampling from local telephone directories, were
screened for psychopathology and were excluded if they
or any of their first-degree relatives had been diagnosed
with SZ/SZS or bipolar affective disorder. Written in-
formed consent was obtained from all participants. The
study complied with the ethics guidelines of the insti-
tutions involved.
All 531 participants were administered a battery of
tests that assessed performance across seven domains of
neurocognitive function, for which evidence of heri-
tability (Cannon et al. 2000) and acceptable effect sizes
of test measures (Heinrichs and Zakzanis 1998) have
been reported. The domains and corresponding tests
were as follows.
General cognitive ability: The National Adult Reading
Test (NART), which estimates prior or premorbid verbal
IQ, and the Shipley Institute of Living Scale, which es-
timates current IQ (by conversion to a Wechsler Adult
Intelligence Scale R [WAIS-R] score).
Sustained attention: Two versions of the visual Con-
tinuous Performance Task—the degraded-stimulus ver-
sion (CPT-DS), which involves an increased demand on
visual encoding, and the identical-pairs version (CPT-
IP), which selectively engages working memory.
Executive function: The FAS version of the Controlled
Oral Word Association Task, which tests verbal fluency.
Verbal memory: The Rey Auditory Verbal Learning
Test, which measures immediate and delayed recall of
word lists, retention after distraction, and errors (i.e.,
intrusions of nonlist words).
Speed of information processing: The Inspection Time
(IT) task, which provides a measure of perceptual en-
coding and speed of processing, unconfounded by mo-
tor-reaction time.
Neurobehavioral features: A structured examination
that evaluated a range of soft neurological signs; in ad-
dition, The Edinburgh Handedness Inventory of hand/
foot/eye preferences.
Personality factors: The Schizotypal Personality Ques-
tionnaire (SPQ) (Raine 1991) and the Temperament
and Character Inventory (TCI) (Cloninger and Svrakic´
1994), both of which were completed by all participants.
We used grade of membership (GoM) analysis (Wood-
bury et al. 1978; Manton et al. 1994) to analyze the test
results, with control individuals providing the baseline
data. GoM is a form of latent structure analysis, directed
at defining a parsimonious number of latent groups or
patterns of responses (representing, e.g., biological pro-
cesses or phenotypes) from complex data sets, and al-
lowing individuals to resemble each group to varying
degrees (rather than classifying them into mutually ex-
clusive clusters, as done in standard latent class analysis).
These properties enable GoM to account for individual
heterogeneity under conditions of high dimensionality
better than alternative methods do, as is the case with
the multiple continuous cognitive traits we measured for
schizophrenia in a modestly sized family sample. Two
sets of parameters are estimated by maximum likelihood
(Woodbury et al. 1978; Manton et al. 1994). One set
represents the latent pure-type groups by the probabil-
ities ( ) that a subject matching the kth group willlkjl
exhibit the ith response for the jth variable. The other
set represents the resemblance of individuals to the
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Figure 1 Association of the CD and CS traits with the clinical
phenotype (SZ/SZS) at different cut-off values of the GoM ( ) scores.gik
The cumulative curves are based on all 76 subjects (47 affected and
29 clinically unaffected) assigned to the CD subtype and all 86 subjects
(60 affected and 26 clinically unaffected) assigned to the CS subtype,
within the sample of 112 families. The CD trait shows a stronger
association with clinical affection status than does the CS trait, over
the entire range above the cut-off at 0.323. Of the affected subjectsgik
assigned to the CD trait, 68% had scores in the range 0.3–0.6 andgik
96% had scores of 0.3–0.8. In comparison, 28% of the affectedgik
subjects assigned to the CS trait had scores of 0.3–0.6 and 75%gik
and had scores of 0.3–0.8. The highest observed score was 0.884g gik ik
for the CD trait and 1.000 for the CS trait.
groups by GoM weights ( ), which range from 0 to 1,gik
are constrained to sum to 1 over the groups for each
subject, and measure the degree to which the ith subject
resembles the kth pure type. The probability that the ith
subject has the lth level of the jth variable is defined by
a binary variable (i.e., or 1). As a taxometricy p 0ijl
procedure, GoM differs from other clustering or factor
analytical methods in that the scores retain full in-gik
formation on individuals and account for all individual
heterogeneity in the data. By assigning a single scoregik
to an individual’s GoM in each multivariate pure type,
the analysis avoids the problem of multiple testing and
the concomitant loss of power due to an increasing num-
ber of degrees of freedom. GoM is independent of dis-
tribution assumptions and is relatively robust to missing
data. In genetic analysis, it combines multivariate con-
tinuous trait variables with different effect sizes or her-
itabilities, resulting in increased power (Kaabi and Els-
ton 2003).
We used the neurocognitive test results, neurobehav-
ioral features, and personality traits as internal variables
to estimate the model parameters. Disease status, posi-
tion within the pedigree, and demographic information
were used descriptively as external variables to provide
estimates of their frequencies for each pure type, con-
ditioned on the model parameters. The data in this stu-
dy were analyzed using the beta 1.01 version of the
DSIGoM software (Decision Systems).
Optimal partitioning of the data (by a maximum-like-
lihood criterion) was obtained with four pure types. Two
of these types, referred to as “cognitive deficit” (CD)
and “cognitively spared” (CS), displayed markedly con-
trasting profiles (table 1), with probabilities of 80.6%
(CD) and 70.0% (CS) of being expressed in subjects with
SZ/SZS and in a proportion of their unaffected relatives.
The CD pure type was characterized by a high proba-
bility of poor performance on the majority of cognitive
tasks, an increased prevalence of nonlocalizing (“soft”)
neurological signs, and non–right-handedness (table 1).
The CS pure type exhibited high scores for psychomet-
ric schizotypy and for traits associated with psychosis
proneness. The remaining two pure types (cognitively
intact and cognitively preserved) had little chance (5%
and 7%, respectively) of expression in affected subjects
and were represented mainly by well-functioning sib-
lings, unaffected parents (some with mild, age-related
cognitive nonoptimality), and controls.
We used the individual-level GoM coefficients (i.e.,
scores, which, for each subject, ranged from 0 to 1gik
for each pure type and summed to 1 over the four pure
types) to classify the probands on the basis of the gik
score indicating their greatest affinity to one of the pure
types: predominantly CD (41 subjects), CS (51 subjects),
or non-CD/CS (20 subjects with low scores for both CD
and CS pure types). On the basis of the proband’s pre-
dominant phenotype assignment, we classified the fam-
ilies into CD, CS, and non-CD/CS groups and examined
the familial aggregation of the scores as continu-gik
ous variables. Intrafamilial aggregation was significant
(analysis of variance [ANOVA] ; ) inFp 1.67 P ! .001
the families with the proband assigned to the CD group
but not in the families with the proband assigned to the
CS or non-CD/CS group (table 2). Next, we analyzed
the association of the scores for the CD and CS traits,gik
as continuous variables, with clinical illness (SZ/SZS) in
family members. The results (fig. 1) indicated an asso-
ciation of the CD trait with SZ/SZS at all cut-offgik
points 0.3, supporting cosegregation of the CD trait
with the clinical phenotype. Finally, to estimate the rel-
ative risk ratio (lr), we compared the prevalence of the
CD and CS types among the first-degree relatives of pro-
bands and among controls. For the CD type, the prev-
alence was 18.9% among relatives and 2.0% among
controls, yielding . By contrast, the CS preva-l p 9.5r
lence was 16.8% among relatives and 14.0% among
controls, yielding for this type.l p 1.2r
The identification of generalized pervasive CD as an
endophenotype in some, but not all, subjects SZ/SZS and
their families suggested that it might characterize a ge-
netically distinct schizophrenia subtype. To test this hy-
pothesis, we conducted a whole-genome scan, with 380
microsatellites from the LMS1-HD5 marker set (Applied
Biosystems), providing an average intermarker distance
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Table 1
Pure-Type Profiles Identified by GoM Analysis (112 Families; 388 Individuals)
VARIABLESa H
PROBABILITIES FOR PURE TYPEblk
CD CS
Cognitively
Intact
Cognitively
Preservedc
Neurocognitive domains:
General ability:
Estimated premorbid IQ (95) .73 84.7 .0 .0 .0
Current IQ (91) .87 84.6 .0 .0 .0
Verbal memory:
Immediate word recall (21) .92 100.0 .0 .0 .0
Delayed word recall (5) .87 71.5 .0 .0 .0
Lexical retrieval:
Verbal fluency, words (26) .64 85.2 .0 .0 .0
Sustained attention:
CPT-DS ( )dL  4.3 .56 91.8 .0 .0 .0
CPT-IP ( )dL  2.2 .59 85.0 .0 .0 .0
Speed of information processing:
Inspection time (36 s) .35 66.5 40.5 .0 72.3
Neurobehavioral features:
Neurological soft signs (3) .30 100.0 10.9 12.1 14.0
Non–right-handed ( )LQ  45 .12 22.4 3.4 8.3 8.3
Personality factors:
Schizotypal symptomsd (23) .95 .0 100.0 .0 .0
Harm avoidancee (19) .50 .0 90.1 .0 .0
Self-transcendencef (19) .62 28.4 79.8 .0 .0
Self-directednessg (37) .66 .0 .0 81.7 65.9
External variables:
Proband … 72.8 67.8 .0 .0
First-degree relative … 27.2 32.9 100.0 100.0
Affected (SZ/SZS) … 80.6 70.0 4.8 6.8
Other diagnosish … 9.5 23.3 45.6 28.0
Female … 37.5 22.1 79.4 37.2
Age 45 years … 45.9 10.0 19.7 96.3
NOTE.—H is an information-content coefficient, estimating the contribution of each var-
iable to the final maximum-likelihood solution ( indicates significant contribution).H  0.10
Important data patterns are shown in bold italics.
a Measures of neurocognitive domains, neurobehavioral features, and personality factors
were used as internal variables defining the pure types (the cut-off values for each test were
the upper and lower bounds of the extreme quantile of the distribution of test scores). The
external variables of the pure types are similarly described by probabilities but were notlk
used in the identification of the pure types. dLp signal-detection index; LQp lateralization
quotient (by Edinburgh Handedness Inventory).
b Pure types are extreme profiles, partitioning the data in accordance with a maximum-
likelihood criterion, and are described by percent probabilities ( ) that an individual ex-lk
pressing completely a given pure type will exhibit the characteristic.
c Age-related.
d Ideas of reference, odd beliefs, suspiciousness, unusual perceptions, constricted affect,
social anxiety, and eccentric behavior (by SPQ).
e Anticipatory worry and fear of uncertainty (by TCI).
f Unusual spiritual experiences and beliefs (by TCI).
g Purposefulness and resourcefulness (by TCI).
h Current or lifetime-ever affective, anxiety, other neurotic, personality, and substance use
disorders.
of 9.81 cM (see table 3 for a list of markers and genetic
distances). For the linkage analysis, we used an inte-
grated genetic map (produced by David Duffy at the
Queensland Institute for Medical Research; see David
Duffy’s QIMR Homepage), which contains interpolated
genetic map positions estimated via locally weighted lin-
ear regression from the physical map (National Center
for Biotechnology Information [NCBI] build 34.3) and
the published deCODE and Marshfield maps. The ge-
nome scan was performed using 93 of the families (34
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Table 2
Characteristics of Families and Family Members Assigned to Cognitive Phenotype Groups
VARIABLE
FINDING IN PHENOTYPE GROUPa
CD CS Non-CD/CSb
Family characteristicsc:
No. of families/probands 41 (34) 51 (42) 20 (17)
Total no. of members 147 (127) 174 (155) 67 (60)
No. affected with SZ/SZS 54 (45) 59 (50) 25 (22)
No. affected who have CD phenotype 47 (38) 0 (0) 0 (0)
No. unaffected who have CD phenotyped 15 (11) 11 (10) 3 (2)
Total no. who have CD phenotype 62 (49) 11 (10) 3 (2)
Familial aggregation of scorese:gik
Square of , between familiesfgik .067 .085 .088
Square of , within familiesfgik .040 .085 .073
F (significance) 1.666 ( )Pp .000 .996 (NS) 1.202 (NS)
For the CD phenotypefgik .554  .143 .243  .192 .087  .108
For the CS phenotypefgik .159  .154 .701  .168 .059  .097
Neurocognitive performanceg:
Estimated premorbid IQf 92.6  9.4 101.4  9.8 105.6  8.9
Current IQf 84.8  12.2 97.4  11.3 107.4  10.0
Immediate word recall (no. of words)f 17.6  5.6 23.8  5.2 27.2  5.7
Delayed word recall (no. of words)f 4.4  2.6 7.1  2.8 9.0  3.0
Verbal fluency (no. of words)f 25.0  8.8 32.1  9.6 38.2  11.3
CPT-DS (dL)h 3.62 (1.4) 5.15 (1.2) 5.48 (1.2)
CPT-IP (dL)h 2.04 (1.3) 3.75 (1.7) 4.2 (1.4)
Inspection time (s)f 46.4  23.6 35.8  12.8 36.2  12.3
NOTE.—After the identification of neurocognitive pure types, each subject was classified as phe-
notypically CD, CS, or non-CD/CS on the basis of the GoM ( ) score showing the greatest positivegik
deviation from the mean for any of the four pure types (i.e., a subject’s for each pure type wasg gik ik
divided by the mean for that pure type).gik
a Families were indexed as CD, CS, or non-CD/CS in accordance with the proband’s cognitive
phenotype.
b Includes the cognitively intact and cognitively preserved pure types from table 1.
c The values in parentheses are the numbers included in the genetic analysis.
d Considered to be affected in the genetic analyses.
e Familial aggregation of the scores as continuous traits (examined by one-way ANOVA) wasgik
highly significant for the CD trait but failed to reach significance for the CS and non-CD/CS phe-
notypes. NS p not significant.
f Values are mean  SD.
g Members displaying each group’s index phenotype were compared across the family groups with
regard to cognitive performance.
h dL p signal-detection index.
Table 3
Markers Typed in the Genome Scan
The table is available in its entirety in the online
edition of The American Journal of Human Genetics.
of which had been assigned to the CD subtype), with a
total of 342 fully characterized members, including 140
classified as “affected”—117 with the diagnosis of SZ/
SZS and 23 nonpsychotic relatives with the CD phe-
notype. Linkage analysis was performed with the pro-
gram package GENEHUNTER-PLUS (Kong and Cox
1997). We used diagnosis and neurocognitive profile as
a bivariate phenotype. For the nonparametric linkage
analysis, all individuals with a SZ/SZS diagnosis, as well
as clinically unaffected relatives classified by GoM as
either CD or CS subtype, were considered to be affected.
Multipoint nonparametric LOD (NPL) scores were cal-
culated with the Spairs statistic and a linear model (fig.
2, left panels). The data were assessed further using or-
dered subset analysis (OSA) (Hauser et al. 2004), in
which the proband’s score for subtype CD was usedgik
as a continuous trait covariate to rank the families in
descending order from highest to lowest CD score (fig.
2, right panels). OSA identifies the rank-ordered subset
of families that provide maximal evidence for linkage
(and no a priori specification of the subset is required).
The statistical significance of the change in the LOD
score between the subset and the overall sample (DLOD)
is evaluated by a permutation test as described elsewhere
(Hauser et al. 2004).
The greatest increase in the LOD score detected by
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Figure 2 NPL analysis and OSA of chromosomes 1–22
Table 4
Results of OSA
Chromosome cM
Nearest
Marker
Maximum
LODa DLOD P
Linked
Families
(%)
1 251.7 D1S2800 .558 .558 .92 11
2 145.8 D2S112 2.458 1.226 .08 78
3 88.7 D3S1285 1.017 .858 .47 10
4 74.3 D4S1592 .983 .459 .64 45
5 78.4 D5S647 2.640 .000 .75 NA
6 20.25 D6S309 3.073 1.546 .01 51
7 54.9 D7S484 .921 .000 .92 NA
8 7.4 D8S264 1.615 .900 .10 29
9 17.3 D9S286 1.371 1.107 .16 33
10 103.8 D10S1686 1.631 1.319 .09 33
11 130.6 D11S925 1.897 1.160 .21 33
12 112.3 D12S346 1.631 1.448 .13 29
13 108.9 D13S173 .701 .684 .61 33
14 104.3 D14S65 1.211 .964 .25 12
15 46.0 D15S978 2.071 1.815 .13 37
16 30.8 D16S3075 1.562 .888 .12 37
17 136.5 D17S928 2.279 .440 .25 40
18 117.8 D18S462 1.554 1.422 .12 33
19 10.6 D19S209 1.797 .000 .73 100
20 33.8 D20S186 1.088 .946 .49 34
21 11.6 D21S1256 .799 .000 .86 NA
22 55.3 D22S423 .738 .698 .36 9
NOTE.—Maximum LOD scores and DLOD from baseline for each chromo-
some, calculated by OSA in family subgroups identified by ordering the family
LOD scores from highest to lowest, on the basis of the GoM coefficients (gik
scores) for the CD type. The baseline LOD score is defined as the LOD score
summed over all families, and it is the difference between the maximum LOD
and DLOD. NAp none of the data sets produced a maximum LOD score greater
than the baseline. Key results are shown in bold italics.
a Denotes the maximum LOD score of all ordered subsets of families.
OSA (table 4) was in the 6p24 region, where a maximum
LOD of 3.07 and DLOD of 1.546 ( ) were ob-P ! .01
tained at marker D6S309 (20.25 cM). The result was
accounted for by the families ranked from 1st to 47th
by the proband’s score for CD (range 0.884–0.306).gik
In addition to the 34 families classified by GoM as sub-
type CD, the 47 OSA-positive families included 11 fam-
ilies assigned to the CS subtype and 2 families assigned
to the non-CD/CS subtype (fig. 3A). Thus, the GoM
endophenotype grouping done prior to analysis, for
which a stringent cut-off value for CD was applied,
proved to be significantly predictive of the observed link-
age to 6p, correctly classifying 72.3% of the OSA-pos-
itive families and 100% of the OSA-negative families
(86.0% correct classification overall).
To corroborate further the prediction that the CD sub-
type is genetically distinct, we performed parametric
multipoint linkage analysis, assuming a CD-susceptibil-
ity allele of dominant inheritance. The gene frequency
was set at 0.02, with penetrance values of 0.5 for het-
erozygote and homozygote disease-allele carriers and
0.001 for noncarriers. In these calculations, individuals
with no SZ/SZS diagnosis and a CD score of 0 were
considered to be unaffected. We genotyped 15 additional
microsatellite markers across the 6p25-22 region (av-
erage distance 1.72 cM) and analyzed the entire chro-
mosome 6 (with 52 markers) separately for the 47 OSA-
positive families and the remaining 46 families. This
analysis revealed clear differences between the two sets
of families (fig. 3B). The combined maximum LOD score
for the 47 families in the CD group increased to 3.32,
again at marker D6S309. By contrast, for the remaining
families, linkage was excluded for the entire region, and
the LOD score at D6S309 was 2.12.
Our linkage findings coincide precisely with the stron-
gest signal on 6p25-p22 reported previously (Straub et
al. 1995) in a large sample of high-density Irish families
with schizophrenia. A follow-up study of the same sam-
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Figure 3 Genetic findings for chromosome 6p in 93 fully char-
acterized families with schizophrenia. A, Classification of the families
as linked or not linked to the 6p24 locus by OSA of the genome scan
data, with use of the proband’s score for the CD type as a contin-gik
uous trait covariate. The positive linkage signal was accounted for by
the 47 families (encircled by the dashed line) with the highest scoresgik
for the CD subtype. B, Linkage curves for chromosome 6p produced
by parametric linkage analysis, conducted separately for the CD-sub-
type and CS-subtype families. Fine mapping of the 6p25-22 region
was done with the addition of 15 microsatellite markers, resulting in
an average intermarker distance of 1.72 cM. The CD-subtype families
had a LOD score of 3.32 at marker D6S309. At that position, non–
CD-subtype families (including the CS and non-CS subtypes) had a
LOD score of 2.12. In the non–CD-subtype families, linkage was
excluded for the entire 6p region.
ple suggested that the region might, in fact, contain two
schizophrenia-susceptibility genes (Straub et al. 2002b).
After the reported association of SNPs in the DTNBP1
gene on 6p22 (Straub et al. 2002a), further studies have
focused on replication and additional association anal-
yses (reviewed by Owen et al. [2004]), leaving the 6p25-
24 region unexplored. Our results, combined with pre-
vious findings (Straub et al. 1995, 2002b; Bailer et al.
2000; Hwu et al. 2000), lead us to suggest that it is the
CD schizophrenia subtype that accounts for the linkage
of schizophrenia to chromosome 6p25-24 and that the
region contains a novel susceptibility gene of relatively
strong effect.
A post hoc comparison between the OSA-positive
families in the CD group and the OSA-negative families
in the CS and non-CD/CS groups (fig. 4) indicated that
SZ/SZS-affected subjects did not differ significantly with
regard to age at onset or to duration or severity of clin-
ical illness, which argues against the idea that CD and
CS subtypes are different stages of a single disease pro-
cess. However, the comparison did reveal differences in
terms of diagnosed psychopathology; “core” schizo-
phrenia was more common among the affected members
of the OSA-positive families, with a ratio of core schizo-
phrenia cases to schizophrenia spectrum disorder cases
(SZ:SZS) of 2.9 in the OSA-positive families, compared
with an SZ:SZS ratio of 2.1 in the OSA-negative fam-
ilies. Further, a greater percentage (12%) of first-degree
relatives in the OSA-negative families had experienced
episodes of bipolar or recurrent depressive disorder,
compared with the percentage of relatives in the OSA-
positive families (6%), suggesting heterogeneity and sus-
ceptibility to both schizophrenia and mood disorders in
the CS-subtype families. As expected, the most salient
differences between the two groups were related to cog-
nitive function (fig. 4), with the CD-subtype families
showing lower scores for general cognitive ability, mem-
ory, executive function, sustained attention, and speed
of information processing. Post hoc logistic regression
analysis (by Wald’s backward stepwise method) identi-
fied verbal memory deficits (delayed word recall), poor
sustained attention (by CPT-DS), and estimated current
and previous IQ (by NART), as the four neurocognitive
parameters (all significant at ) that together clas-P ! .01
sified correctly 91.8% of probands (combined sensitivity
91.2%; specificity 92.3%) as subtype CD or CS, sug-
gesting that, in future genetic studies, efficient endo-
phenotype ascertainment may be possible with an ab-
breviated neurocognitive-screening battery.
Having identified a cognitive subtype of schizophrenia
linked to the 6p25-22 region, we acknowledge the lim-
itation of the modest sample size in the present study as
a constraint on our effort to have a more comprehensive
characterization of a range of possible neurocognitive
endophenotypes in this disorder. The apparent lack of
familiality in the CS subtype is attributable to further
heterogeneity and insufficient power to resolve familial
aggregation, as a result of smaller effect sizes of the per-
sonality-trait measures defining this endophenotype (in
contrast to relatively large effect sizes for the neurocog-
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Figure 4 Post hoc phenotypic comparisons of the families included in the genome scan and OSA and averaged test performance profiles
of the members ( ) of the 93 families included in the genome scan and OSA. The differences (by t test) between CD-subtype and non–np 342
CD-subtype (including the CS and non-CS subtypes) families were significant for previous or premorbid IQ, verbal memory, and sustained
attention ( ); verbal fluency ( ); speed of information processing ( ); and non–right-handedness ( ). NeurocognitiveP ! .001 P ! .01 P ! .05 P ! .05
domains: 1 p previous or premorbid IQ; 2 p current IQ; 3 p verbal memory, immediate recall; 4 p verbal memory, delayed recall; 5 p
verbal fluency; 6 p sustained attention CPT-IP/dL; 7 p sustained attention CPT-DS/dL; 8 p slow information processing (by IT task).
Neurobehavioral features: 9p neurological soft signs; 10p handedness (lateralization quotient). Personality traits: 11p schizotypal symptoms;
12 p harm avoidance; 13 p self-transcendence; 14 p self-directedness.
nitive markers identifying the familial CD endopheno-
type). Future studies should investigate the cognitive ar-
chitecture of the CS group in greater detail. This group
is characterized by more complex symptomatology (sys-
tematized delusions, abnormalities of high-order rea-
soning, etc.) than is the CD group, reflecting a plausible
distinction between the two groups in terms of perva-
sively reduced cognitive efficiency in CD-subtype indi-
viduals versus dysfunctional cognitive control in the
CS-subtype individuals (a similar distinction has been
proposed by Brebion et al. [2005]). Although powerful
enough for reliable assessment of reduced cognitive ef-
ficiency, our present battery of tests may not be targeting
the essential features of a putative CS endophenotype
likely to display abnormalities in complex functions,
such as self-monitoring, source attribution, and cogni-
tive inhibition, as well as in their modulation by external
(environmental) and internal (affective) background
factors.
Notwithstanding such caveats, our data bring back to
center stage the critical issue of phenotypic and etiological
diversity in schizophrenia. The neurocognitive tests that
we used to dissect the disease phenotype outlined a rel-
atively homogeneous, familial, genetically distinct subtype
closely corresponding to the dementia praecox described
by Kraepelin (1909). In our sample, this subtype ac-
counted for ∼30% of families on the basis of the more
stringent cut-off value in our GoM analysis and forgik
up to ∼50% of families on the basis of the OSA of the
linkage data. If this sample is representative of other Eu-
ropean populations, the observed prevalence of disease
subtypes would have serious implications for the power
of genetic studies—traditionally based on broad DSM-IV
and ICD-10 diagnostic categories—to detect linkage and
association. Parsing the phenotypic complexity of schizo-
phrenia may open the way to a more informed search for
specific pathogenetic pathways and underlying genetic
mechanisms. Neurocognitive profiling with the proposed
abbreviated battery, which comprises the most informa-
tive tests, should facilitate research, focusing on a more
crisply defined, familial subtype of schizophrenia.
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Web Resources
The URLs for data presented herein are as follows:
Decision Systems, http://www.dsisoft.com/ (for DSIGoM soft-
ware and analysis)
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davidD/ (for integrated genetic map)
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